Related Experiment Video
Updated: May 26, 2026

Pluripotent Stem Cell Derived Cardiac Cells for Myocardial Repair
Published on: February 3, 2017
Strategies for replacing myocytes with induced pluripotent stem in clinical protocols
Fumiyuki Hattori1, Keiichi Fukuda
1Department of Cardiology, Keio University School of Medicine, Tokyo, 160-8582, Japan. hattori.fumiyuki.ef@asubio.co.jp
Abstract:
Induced pluripotent stem (iPS) cells can be established via forced epigenetic reprogramming of various somatic cells and selection based on given criteria. Human iPS cells are preferred for clinical applications because they present fewer ethical concerns than embryonic stem cells. However, technical issues of stability and safety must be fully validated before clinical use. Moreover, heart regenerative therapies would require approximately 10(9) cardiomyocytes per person, necessitating the following technical considerations: (1) genetically and epigenetically stable scaling up of the iPS cells, (2) efficient and reproducible differentiation, and (3) highly reliable cell purification. Furthermore, (4) strategies for efficient iPS transplantation, rapid maturation, and functional integration of grafted cardiomyocytes into the host myocardium are critical unmet technologies. Herein, we discuss current progress and unmet problems for the realization of heart regenerative therapy.
More Related Videos
Related Concept Videos
Induced Pluripotent Stem Cells
Induced Pluripotent Stem Cells
Somatic cells are...
Induced Pluripotent Stem Cells
EPS and iPS Cells in Disease Research
iPS Cell Differentiation
Stem Cell Culture

